Active Ingredient History
Daunorubicin, also known as daunomycin, is a chemotherapy medication used to treat cancer. Specifically, it is used for acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and Kaposi's sarcoma. Similar to doxorubicin, daunorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis. This inhibits the progression of the enzyme topoisomerase II, which relaxes supercoils in DNA for transcription. Daunorubicin stabilizes the topoisomerase II complex after it has broken the DNA chain for replication, preventing the DNA double helix from being resealed and thereby stopping the process of replication. On binding to DNA, daunomycin intercalates, with its daunosamine residue directed toward the minor groove. It has the highest preference for two adjacent G/C base pairs flanked on the 5' side by an A/T base pair. Daunorubicin should only be administered in a rapid intravenous infusion. It should not be administered intramuscularly or subcutaneously, since it may cause extensive tissue necrosis. It should also never be administered intrathecally (into the spinal canal), as this will cause extensive damage to the nervous system and may lead to death. NCATS
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Leukemia, Myeloid, Acute (approved 1979)
Neuroblastoma (approved 1979)
Precursor Cell Lymphoblastic Leukemia-Lymphoma (approved 1979)
Aged (Phase 3)
Anemia (Phase 2)
Anemia, Refractory (Phase 3)
Bone Marrow Cells (Phase 2)
Breast Neoplasms (Phase 1)
Down Syndrome (Phase 3)
Hematologic Neoplasms (Phase 1)
HIV Infections (Phase 3)
Immunoglobulins (Phase 3)
Leukemia (Phase 3)
Leukemia, Eosinophilic, Acute (Phase 3)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 4)
Leukemia, Lymphoid (Phase 4)
Leukemia-Lymphoma, Adult T-Cell (Phase 1/Phase 2)
Leukemia, Monocytic, Acute (Phase 3)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1/Phase 2)
Leukemia, Myeloid (Phase 3)
Leukemia, Myeloid, Acute (Phase 4)
Leukemia, Myelomonocytic, Acute (Phase 3)
Leukemia, Myelomonocytic, Chronic (Phase 3)
Leukemia, Promyelocytic, Acute (Phase 4)
Lymphoma (Phase 3)
Lymphoma, Large-Cell, Immunoblastic (Phase 3)
Lymphoma, Non-Hodgkin (Phase 2)
Mucositis (Phase 3)
Multiple Myeloma (Phase 3)
Mutation (Phase 2)
Myelodysplastic Syndromes (Phase 3)
Myeloma Proteins (Phase 3)
Myeloproliferative Disorders (Phase 3)
Neoplasms (Phase 2)
Neutropenia (Phase 3)
Polycythemia Vera (Phase 1/Phase 2)
Primary Myelofibrosis (Phase 1/Phase 2)
Renal Insufficiency, Chronic (Phase 3)
Sarcoma (Phase 3)
Sarcoma, Kaposi (Phase 3)
Sarcoma, Myeloid (Phase 3)
Stents (Phase 2)
Testicular Neoplasms (Phase 3)
Thrombocythemia, Essential (Phase 1/Phase 2)
Thrombocytopenia (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
